Co-expression and predictive value of HER family members for the response to therapy with cetuximab in patients with metastatic colorectal cancer.

被引：0
|
作者：
Khelwatty, Said A. [1 ]
Puvanenthiran, Soozana [1 ]
Essapen, Sharadah [2 ]
Bagwan, Izhar [2 ]
Seddon, Alan M. [1 ]
Modjtahedi, Helmout [1 ]
机构：
[1] Kingston Univ London, Kingston Upon Thames, Surrey, England
[2] Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
350
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer"
    Benjamin, Laura E.
    CANCER RESEARCH, 2016, 76 (15) : 4309 - 4310
  • [22] Predictive value of heparanase expression in the palliative therapy of pancreatic cancer.
    Caca, K
    Kronberg, J
    Tannapfel, A
    Wittekind, C
    Moessner, J
    Schoppmeyer, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 855S - 855S
  • [23] Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer
    Aguiar, S
    Lopes, A
    Soares, FA
    Rossi, BM
    Ferreira, FO
    Nakagawa, WT
    Carvalho, AL
    Filho, WJD
    EJSO, 2005, 31 (08): : 863 - 868
  • [24] Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
    J Souglakos
    J Philips
    R Wang
    S Marwah
    M Silver
    M Tzardi
    J Silver
    S Ogino
    S Hooshmand
    E Kwak
    E Freed
    J A Meyerhardt
    Z Saridaki
    V Georgoulias
    D Finkelstein
    C S Fuchs
    M H Kulke
    R A Shivdasani
    British Journal of Cancer, 2009, 101 : 465 - 472
  • [25] Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
    Souglakos, J.
    Philips, J.
    Wang, R.
    Marwah, S.
    Silver, M.
    Tzardi, M.
    Silver, J.
    Ogino, S.
    Hooshmand, S.
    Kwak, E.
    Freed, E.
    Meyerhardt, J. A.
    Saridaki, Z.
    Georgoulias, V.
    Finkelstein, D.
    Fuchs, C. S.
    Kulke, M. H.
    Shivdasani, R. A.
    BRITISH JOURNAL OF CANCER, 2009, 101 (03) : 465 - 472
  • [26] PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
    Frattini, M.
    Saletti, P.
    Romagnani, E.
    Martin, V.
    Molinari, F.
    Ghisletta, M.
    Camponovo, A.
    Etienne, L. L.
    Cavalli, F.
    Mazzucchelli, L.
    BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1139 - 1145
  • [27] Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
    Jehn, C. F.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    BRITISH JOURNAL OF CANCER, 2012, 106 (02) : 274 - 278
  • [28] Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
    C F Jehn
    L Böning
    H Kröning
    K Possinger
    D Lüftner
    British Journal of Cancer, 2012, 106 : 274 - 278
  • [29] PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
    M Frattini
    P Saletti
    E Romagnani
    V Martin
    F Molinari
    M Ghisletta
    A Camponovo
    L L Etienne
    F Cavalli
    L Mazzucchelli
    British Journal of Cancer, 2007, 97 : 1139 - 1145
  • [30] Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer
    Macarulla, Teresa
    Javier Ramos, Francisco
    Elez, Elena
    Capdevila, Jaume
    Peralta, Sergio
    Tabernero, Josep
    CLINICAL COLORECTAL CANCER, 2008, 7 (05) : 300 - 308
12345